Subscribe
law_istock-638601140_bcfc-
BCFC / iStockphoto.com
29 September 2017Americas

AbbVie and Amgen settle Humira clash

AbbVie has settled its patent dispute over Amgen’s proposed biosimilar for Humira (adalimumab), a drug used to treat multiple types of arthritis as well as psoriasis.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
AbbVie, Abbott fight bid to force FTC discovery disclosure
6 April 2021   Pharmaceutical companies defending an antitrust lawsuit have fought back against attempts to get them to disclose confidential information garnered through discovery during the litigation to the US Federal Trade Commission.
Big Pharma
Amgen asks SCOTUS to reject Roche petition
14 April 2021   Amgen subsidiary Immunex has asked the US Supreme Court not to review a Federal Circuit decision that found the company did not patent the same rheumatoid arthritis invention twice.
Americas
Amgen sues generic drug maker over bone treatments
4 May 2023   Lawsuit concerns multibillion-dollar bone-strengthening drugs | Alleged dearth of information provided to patent owner before biologics licence application was approved.


Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024

Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024
Unified Patent Court
‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute
26 September 2024
Unified Patent Court
Interview: Klaus Grabinski, UPC Court of Appeal president
24 September 2024
Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024
Unified Patent Court
Does the UPC offer a fresh take on patent validity?
5 September 2024

More on this story

Americas
AbbVie, Abbott fight bid to force FTC discovery disclosure
6 April 2021   Pharmaceutical companies defending an antitrust lawsuit have fought back against attempts to get them to disclose confidential information garnered through discovery during the litigation to the US Federal Trade Commission.
Big Pharma
Amgen asks SCOTUS to reject Roche petition
14 April 2021   Amgen subsidiary Immunex has asked the US Supreme Court not to review a Federal Circuit decision that found the company did not patent the same rheumatoid arthritis invention twice.
Americas
Amgen sues generic drug maker over bone treatments
4 May 2023   Lawsuit concerns multibillion-dollar bone-strengthening drugs | Alleged dearth of information provided to patent owner before biologics licence application was approved.

More on this story

Americas
AbbVie, Abbott fight bid to force FTC discovery disclosure
6 April 2021   Pharmaceutical companies defending an antitrust lawsuit have fought back against attempts to get them to disclose confidential information garnered through discovery during the litigation to the US Federal Trade Commission.
Big Pharma
Amgen asks SCOTUS to reject Roche petition
14 April 2021   Amgen subsidiary Immunex has asked the US Supreme Court not to review a Federal Circuit decision that found the company did not patent the same rheumatoid arthritis invention twice.
Americas
Amgen sues generic drug maker over bone treatments
4 May 2023   Lawsuit concerns multibillion-dollar bone-strengthening drugs | Alleged dearth of information provided to patent owner before biologics licence application was approved.

More features

President Trump 2.0: Five major areas to watch
China’s new policies on foreign investment in healthcare and biotech
Startup CFO’s betrayal is a lesson in preparing for the worst
Sandoz lands reduced antitrust award of $70m
New president’s to-do list: Patent bills, non-competes, USPTO director?
Sanofi subsidiary fends off $450m trade secrets case
Regulatory expert joins White & Case
Teva faces $500m fine for antitrust breaches over MS drug